Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by University of Oslo.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
Marianne Bollestad, University of Oslo Identifier:
First received: February 7, 2012
Last updated: February 9, 2012
Last verified: February 2012

The prevalence of extended spectrum betalactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades.

The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents.

Samples are gathered in primary care setting.

Urinary Tract Infections

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?

Resource links provided by NLM:

Further study details as provided by University of Oslo:

Biospecimen Retention:   Samples With DNA


Estimated Enrollment: 300
Study Start Date: February 2012
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
ESBL producing bacteria
Group of patients with identified ESBL producing bacteria in a urine sample taken in a primary care setting.
Non-ESBL urinary tract infection
Urinary tract infection found in sample taken in a primary care setting where ESBL producing bacteria are not found.


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The study population will be selected from all patients ages 16 and over who are diagnosed with an urinary tract infection where an ESBL producing bacteria (E. coli or K. Pneumoniae) is found. The urinary tract infection must be diagnosed and treated in a primary care setting.


Inclusion Criteria:

- All patients were urinary sample taken in a primary care setting shows significant growth of ESBL producing K. pneumoniae or E. coli.

Above age 16.

Exclusion Criteria:

- Sample from patients in hospital care or living in nursing home facilities. Inability to understand and sign information leaflet.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01531023

Contact: Marianne Bollestad, Md +4798488454

Sponsors and Collaborators
University of Oslo
Study Director: Morten Lindbaek, Md PhD University of Oslo
  More Information

No publications provided

Responsible Party: Marianne Bollestad, MD, University of Oslo Identifier: NCT01531023     History of Changes
Other Study ID Numbers: 2011/2214-3
Study First Received: February 7, 2012
Last Updated: February 9, 2012
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Keywords provided by University of Oslo:
Extended-Spectrum Betalactamese Producing Bacteria

Additional relevant MeSH terms:
Communicable Diseases
Urinary Tract Infections
Urologic Diseases processed this record on November 20, 2014